ANDA 204421, held by Aurobindo Pharma Ltd. Tramadol Hydrochloride.
As of Nov 16, 2026, ANDA 204421 (Tramadol Hydrochloride), held by Aurobindo Pharma Ltd, was first approved by FDA on Oct 20, 2015, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 20, 2015 | Original application | Approved |
| Tramadol Hydrochloride100MG · tablet, extended release;oral | Tramadol Hydrochloride | Discontinued |
| Tramadol Hydrochloride200MG · tablet, extended release;oral | Tramadol Hydrochloride | Discontinued |
| Tramadol Hydrochloride300MG · tablet, extended release;oral | Tramadol Hydrochloride | Discontinued |
| Sep 21, 2018 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 18, 2018 | Supplement 6REMS | Approved | None posted |
| Sep 11, 2018 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 29, 2017 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 21, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 20, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters